

Instagraft-patent approved in Israel

S2Medical AB (publ)("the Company") has today received the notice that Israeli authorities intend to grant patent approval for the Company's instagraft technology in Israel.

The instagraft technology is a surgical instrument that can be used for minimally invasive skin transplantation and is intended to move this procedure from specialist units out to the primary healthcare units. This would result in a higher number of patients suffering from chronic ulcers getting access to skin transplantation and thereby being able to heal their wounds.

"The instagraft technology is one of our most valuable intellectual assets. Through our strong presence in the Middle East we hope to be able to help even more patients getting their wounds healed and we believe that this technology will play a crucial role. We are there for very happy to reach patent protection in yet another country in this region" says the Company's CEO Petter Sivlér.

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-09-2022 15:34 CET.

Contact Details

Petter Sivlér – CEO, S2Medical AB (publ) Telephone: +46 (0)8-70 000 50 E-mail: <u>petter.sivler@s2m.se</u>

Certified Adviser

Vator Securities AB Telephone +46 (0)8-580 065 99 Website: www.vatorsec.se E-mail: ca@vatorsec.se

About S2Medical

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process, with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thereby reduces both suffering for patients and costs for health care.

Share's ticker: S2M

Share's ISIN-code: SE0011725084